Use of Antimony in the Treatment of Leishmaniasis: Current Status and Future Directions. (8th June 2011)

• Record Type: Journal Article
• Authors: Haldar, Arun Kumar; Sen, Pradip; Roy, Syamal
• Other Names: Majumder Hemanta K. Academic Editor.
• Is Part Of: Molecular biology international. Volume 2011(2011)
• Publication Date: 2011-06-08
• Subjects: Molecular biology -- Periodicals; Molecular Biology; Molecular biology; Electronic journals; Periodical; Fulltext; Internet Resources; Periodicals; Periodicals; 572.8
• DOI: 10.4061/2011/571242
• Languages: English
• ISSNs: 2090-2182

Abstract

Abstract : In the recent past the standard treatment of kala-azar involved the use of pentavalent antimonials Sb(V). Because of progressive rise in treatment failure to Sb(V) was limited its use in the treatment program in the Indian subcontinent. Until now the mechanism of action of Sb(V) is not very clear. Recent studies indicated that both parasite and hosts contribute to the antimony efflux mechanism. Interestingly, antimonials show strong immunostimulatory abilities as evident from the upregulation of transplantation antigens and enhanced T cell stimulating ability of normal antigen presenting cells when treated with Sb(V) in vitro . Recently, it has been shown that some of the peroxovanadium compounds have Sb(V)-resistance modifying ability in experimental infection with Sb(V) resistant Leishmania donovani isolates in murine model. Thus, vanadium compounds may be used in combination with Sb(V) in the treatment of Sb(V) resistance cases of kala-azar.